Targeting composite treatment of type 2 diabetes in middle-income countries--walking a tightrope between hyperglycaemia and the dangers of hypoglycaemia.

Middle-income countries need a rational and cost-effective approach to optimise management of type 2 diabetes mellitus (T2DM). There is a paucity of data from such countries on the extent of hypoglycaemia and its consequences for their healthcare systems. This review provides the context for health policy change and evaluates available data on diabetes complications, focusing on hypoglycaemia in T2DM patients in non-Western countries.